Singulair is a brand name for the medication montelukast, which belongs to a class of drugs called leukotriene receptor antagonists. It is primarily prescribed for the treatment of asthma and seasonal allergies. Here is some information about Singulair:


Treatment of Asthma and Allergies

Singulair (montelukast) is commonly used to manage the symptoms of asthma in both adults and children. It helps to control and prevent asthma symptoms, such as wheezing, shortness of breath, chest tightness, and coughing. It can also be used for the prevention of exercise-induced bronchoconstriction.

Additionally, Singulair is used for the relief of seasonal allergic rhinitis (hay fever) symptoms, including sneezing, runny nose, itching, and nasal congestion.

Mechanism of Action

Singulair works by blocking the action of leukotrienes, which are inflammatory substances released in the body in response to certain triggers, such as allergens or irritants. By blocking leukotrienes, Singulair helps to reduce inflammation in the airways and alleviate symptoms associated with asthma and allergies.

Dosage and Administration

Singulair is available in tablet form and is typically taken orally, usually once daily in the evening for asthma control or seasonal allergies. The dosage will vary depending on the age of the patient and the specific condition being treated. It is important to follow the dosage instructions provided by a healthcare professional.

Precautions and Potential Side Effects

Singulair is generally well-tolerated, but like any medication, it can have potential side effects. Common side effects may include headache, gastrointestinal disturbances (such as nausea or diarrhea), and flu-like symptoms. These side effects are usually mild and temporary.

Rarely, Singulair may cause more serious side effects, such as mood or behavior changes, including agitation, irritability, anxiety, depression, or suicidal thoughts. It is important to seek medical attention if any concerning side effects occur.

Consultation with Healthcare Professional

Singulair is a prescription medication, and its use should be supervised by a healthcare professional. It is important to consult with a doctor or pulmonologist/allergist to discuss your specific condition, determine the appropriate dosage, and assess any potential underlying causes of asthma or allergies.

WARNING: Please consult with a healthcare professional or doctor for personalized advice and guidance regarding the use of Singulair or any other medication for the treatment of asthma or allergies. They will be able to provide specific instructions based on your medical history and individual needs.


  1. ^ “Montelukast (Singulair) Use During Pregnancy” 13 December 2019. Retrieved 4 March 2020.
  2. Jump up to:a b c “Singulair 10 mg film-coated tablets – Summary of Product Characteristics (SmPC)”electronic medicines compendium (emc). Retrieved 23 December 2018.
  3. ^ “Singulair- montelukast sodium granule Singulair- montelukast sodium tablet, chewable Singulair- montelukast sodium tablet, film coated”DailyMed. 29 April 2020. Retrieved 12 October 2020.
  4. Jump up to:a b “Elsevier – Drug Monograph │Montelukast”Elsevier’s Healthcare Hub. 4 March 2020. Retrieved 27 January 2023. Montelukast and its metabolites are excreted almost exclusively via the bile; less than 0.2% of the drug is excreted in urine. Mean elimination half-life (half-life) of montelukast is 2.7 to 5.5 hours in healthy young adults.
  5. Jump up to:a b c d e f g h i j k l m “Montelukast Sodium Monograph for Professionals” AHFS. Retrieved 23 December 2018.
  6. ^ Grainger J, Drake-Lee A (October 2006). “Montelukast in allergic rhinitis: a systematic review and meta-analysis”. Clinical Otolaryngology. Wiley. 31 (5): 360–367. doi:10.1111/j.1749-4486.2006.01276.xPMID 17014443S2CID 27200676.
  7. ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 269. ISBN 9780857113382.
  8. ^ “The Top 300 of 2020”ClinCalc. Retrieved 7 October 2022.
  9. ^ “Montelukast – Drug Usage Statistics”ClinCalc. Retrieved 7 October 2022.
  10. ^ “Montelukast Sodium”The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
  11. ^ Cardet JC, Akin C, Lee MJ (October 2013). “Mastocytosis: update on pharmacotherapy and future directions”Expert Opinion on Pharmacotherapy14 (15): 2033–2045. doi:10.1517/14656566.2013.824424PMC 4362676PMID 24044484.
  12. ^ “Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions”. Retrieved 19 September 2019.
  13. Jump up to:a b “Singulair (montelukast) and All Generics: Strengthened Boxed Warning”U.S. Food and Drug Administration (FDA). 4 March 2020. Retrieved 4 March 2020. PUBLIC DOMAIN This article incorporates text from this source, which is in the public domain.
  14. Jump up to:a b “Updated Information on Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR)”U.S. Food and Drug Administration (FDA). 12 June 2009. Archived from the original on 14 November 2017. Retrieved 1 March 2017.
  15. ^ “”
  16. Jump up to:a b “FDA Requires Stronger Warning About Risk of Neuropsychiatric Events Associated with Asthma and Allergy Medication Singulair and Generic Montelukast”U.S. Food and Drug Administration (FDA) (Press release). 4 March 2020. Retrieved 4 March 2020. PUBLIC DOMAIN This article incorporates text from this source, which is in the public domain.
  17. Jump up to:a b c d “FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis”U.S.Food and Drug Administration (FDA). 4 March 2020. Retrieved 4 March 2020. PUBLIC DOMAIN This article incorporates text from this source, which is in the public domain.
  18. ^ “Artesunate Amodiaquine Winthrop (artesunate, amodiaquine) | summary of product characteristics. Gentilly, France: Sanofi-aventis; August 2010” (PDF). Archived from the original (PDF) on 24 October 2016. Retrieved 24 October 2016.
  19. ^ German P, Greenhouse B, Coates C, Dorsey G, Rosenthal PJ, Charlebois E, et al. (March 2007). “Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz”Clinical Infectious Diseases44 (6): 889–891. doi:10.1086/511882PMID 17304470.
  20. ^ Backman JT, Filppula AM, Niemi M, Neuvonen PJ (January 2016). “Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions”. Pharmacological Reviews68 (1): 168–241. doi:10.1124/pr.115.011411PMID 26721703S2CID 29099906.
  21. ^ Scott JP, Peters-Golden M (September 2013). “Antileukotriene agents for the treatment of lung disease”. American Journal of Respiratory and Critical Care Medicine188 (5): 538–544. doi:10.1164/rccm.201301-0023PPPMID 23822826.
  22. ^ “New Strategies for Restoring Myelin on Damaged Nerve Cells”Neuroscience News.
  23. ^ 5,565,473
  24. ^ “Drugs covered by patent 5,565,473. Claims, international patent equivalents, patent expiration dates, and freedom to operate”Deep knowledge on small-molecule drugs and the global patents covering them.
  25. ^ “FDA approves first generic versions of Singulair to treat asthma, allergies”. 3 August 2012. Retrieved 15 August 2012.
  26. ^ “U.S. Reexamines Merck’s Singulair Patent”. Thompson Reuters. 28 May 2009.
  27. ^ “Merck Says U.S. Agency Upholds Singulair Patent”. Thompson Reuters. 17 December 2009.
  28. ^ Rubenstein S (28 April 2008). “FDA Sneezes at Claritin-Singulair Combo Pill”The Wall Street Journal.
  29. ^ “Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast”Schering-Plough (Press release). 25 April 2008. Archived from the original on 24 September 2008. Retrieved 17 March 2020.
  30. ^ Li JK (2006). “8”Laughing Gas, Viagra, and Lipitor: The Human Stories Behind the Drugs We Use. Oxford University Press. p. 234. ISBN 978-0195300994. Retrieved 26 November 2017.